GLP-1 · Pharma · 2026

Win the GLP-1 brand war.
Bundle Fitrofy with
your molecule.

Three rings of patient guidance — so prescribers prefer your brand. Don't just sell the drug. Sell the outcome.

Book a pharma demo
60sDiet capture Voice· Text · Photo Multi-slotRecommendations
The Pharma Reality

50+ brands. Same molecule.
How do you win?

The patent expired in March 2026. The price war already started. Differentiation is no longer in the molecule — it's in what surrounds it.

The Challenge
Same molecule, 50+ brands
Every generic is chemically identical semaglutide.
Price war already started
₹1,290 to ₹4,500 — race to the bottom.
Doctors have no reason to prefer
Without differentiation, it's just MR push.
Patients drop off in weeks
No guidance → poor outcomes → doctor distrust.
Your Brand + Fitrofy
Drug + AI nutrition coach
Only brand that ships with daily guidance built in.
Doctor loyalty
Prescribers prefer brands with better outcomes.
Patient stickiness
Protein and fiber tracking keeps patients engaged for the long haul.
Outcomes data flows to you
Real-world nutrition + weight data, anonymized, into your CRM.
Doctor prescribes › Patient gets Fitrofy › AI tracks protein, fiber, score › Better outcomes → Brand loyalty.
Market Reality

GLP-1 is going
mass-market.

The generics race is on. Multi-year runway. Move first.

Was ₹16,400 / mo
₹2,000/mo
↓ 90% price crash
Semaglutide patent expired March 2026 — 40+ companies, 50+ generics now in market.
250M+
Obese / overweight adults
India's addressable population.
~0 → 5%
Penetration in 3–5 yrs
Low penetration today. Multi-year runway to capture.
₹5,000 Cr
Market by 2030
5× growth from today's base.

Every GLP-1 patient needs protein monitoring and gut-health tracking. That's the play.

The Clinical Problem

Patients drop off in 6 weeks.
Your brand pays the price.

GLP-1 suppresses appetite — but without nutrition guidance, three clinical issues drive patients off your molecule. Refill rates collapse. Doctors lose trust. MR effort wasted.

Muscle loss

Low appetite → insufficient protein intake → lean mass depletion and metabolic slowdown.

Metabolic shifts

Kidney stress, liver enzyme changes, thyroid markers — all need close nutrition monitoring.

Gut & fiber gap

Reduced eating → low fiber intake → digestive issues and microbiome disruption.

Every patient who drops off is a refill you lose, an MR call wasted, and a prescriber who switches brands.
The Solution

AI Nutrition Companion.
Six pillars. One stack.

Built before the AI era. Already serving 80,000 users a month. The GLP-1 layer plugs into rails that already work.

The Diet Plan
  • Personalised plans
  • Recipes
  • Macro tracking
  • Multiple options per slot
Verified Database
  • Amity University verified
  • Nutriscore on 25K+ items
  • Glycemic load factor
  • Home · packaged · restaurant
Algorithms + APIs
  • Dietitian-verified logic
  • REST APIs
  • PWA — 3-day integration
  • White-labelled deployment
Dietitian Dashboard
  • Plan creation & sharing
  • Client engagement tracking
  • Macros · weight · trends
  • Quick search & support
Cloud Infrastructure
  • GCP-scalable
  • Admin dashboard
  • Daily · weekly insights
  • Enterprise-grade security
Market Traction
  • 15+ live clients
  • 80K users / month
  • 2+ years operations
  • Industry endorsements
Built for Obesity · Diabetes · Cholesterol · Hypertension · PCOS
Pricing

Priced like a feature.
Worth like a moat.

For pharma partners
₹50 / patient / month
2.5% of the drug cost.

Full Naysha AI + Diet Plans + Dietitian Dashboard. Custom condition protocols for GLP-1. Outcomes data flows back to you.

Talk to us
Live in 3 days · REST API · PWA · WhatsApp · White-label · Amity-certified · GCP-secure
Book a pharma demo

Move before
the market does.

30-min call. We'll walk through your molecule, your TG, your launch plan, and our integration in under a week.

Book a demo